News

Today, Therapeutic Guidelines launched a new desktop app experience with elevated designs, enhanced search features, modern layouts and intuitive navigation to streamline clinical workflows and positively impact patient care outcomes.

The December issue marks a significant milestone as Professor Michael Kidd AO, Australia’s Chief Medical Officer, pens an editorial celebrating Australian Prescriber’s 50th anniversary.

Therapeutic Guidelines announces a strategic partnership to deliver ObesiD, a new clinical resource developed by Advanced Pharmacy Australia (AdPha). The partnership was announced by AdPha President Tom Simpson today at Medicines Management 2025.

Therapeutic Guidelines has introduced a series of significant app updates aimed at improving usability, accessibility and clinical workflow efficiency.

The October issue of Australian Prescriber covers medications for ADHD in children and adolescents, how to select and use oral anticoagulants for AF and VTE, new Australasian consensus recommendations for screening and management of gestational diabetes and more.

Therapeutic Guidelines is pleased to announce the release of the revised Oral and Dental guidelines. This marks the fourth revision to the guidelines involving 16 expert group members and 12 external reviewers.

The August issue features a practical guide on how to safely stop oral corticosteroids following short-term and longer-term use. It covers choosing an NSAID for pain, identifying potentially inappropriate medicines in older people, how to avoid pre-laboratory errors and more.

The June issue provides an update on long and shorter-acting contraceptive methods available in Australia. It covers pharmacogenomics to personalise drug therapy, the management of psoriasis in primary care, medicines for treating opioid dependence and more.

Therapeutic Guidelines has expanded its Antibiotic guidelines with an extensive multidisciplinary update with more than 200 revised and new clinical topics.

The constitution of Therapeutic Guidelines Limited stipulates that the Board shall comprise nine Directors.

Therapeutic Guidelines is pleased to announce the release of the revised Psychotropic and Cardiovascular guidelines (selected clinical topics).

This year marks a momentous milestone in the history of Australian Prescriber, as we celebrate its 50-year anniversary.

The issue spotlights the timely topic of therapeutic use of vapes for smoking cessation and nicotine dependence and more.

Therapeutic Guidelines has launched a new technology platform and mobile app to support more frequent content updates and modernise authentication processes. Our customers can download the new app from the Apple or Google Play Store. Major content updates to Palliative Care and Rheumatology are now available. Also, users can access a significant update to Toxicology and Toxicology, plus more than 100 additional updates across other guidelines.

The new issue addresses 2 challenges in clinical practice: medicine shortages and inhaler devices for people with asthma or chronic obstructive pulmonary disease (COPD) and more.

In the coming weeks, customers will need to download a new mobile app from the Apple or Google Play Store.

The issue highlights polycystic ovary syndrome, needlestick injuries and other blood or body fluid exposures in primary care, and more.

The new release of Australian Prescriber covers biologic treatments for severe asthma, obstructive sleep apnoea management, the 2023 Australian Guideline for Assessing and Managing Cardiovascular Disease Risk, and more.

Due to server maintenance Therapeutic Guidelines will be unavailable on 14 March from 6.30pm to 9:30pm (AEDT).

The new release of Australian Prescriber covers the management of pre-existing diabetes prior to and during pregnancy, hypercholesterolaemia, eosinophilic oesophagitis, and the concept of therapeutic inertia. Also, a case study investigates a body builder’s severe liver injury after using the supplement RAD-140 (a SARM).